-+ 0.00%
-+ 0.00%
-+ 0.00%

ENANTA PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN THE RESOLVE PHASE 2B/3 STUDY OF ZELICAPAVIR, A POTENTIAL FIRST-IN-DISEASE TREATMENT FOR RESPIRATORY SYNCYTIAL VIRUS (RSV)

Reuters·10/26/2026 11:00:01

Please log in to view news